Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **immunological synapse** is a specialized, dynamic cellular junction that forms at the contact point between a lymphocyte (such as a T cell or natural killer cell) and an antigen-presenting cell (APC) or target cell[1][2][3][5]. This structure is crucial for the immune system, facilitating the recognition of peptide antigens bound to major histocompatibility complex (MHC) molecules presented by APCs, thereby initiating and regulating T cell activation and effector functions[1][4][6]. Structurally, the immunological synapse is often described as having a “bull's-eye” organization with concentric supramolecular activation clusters (SMACs), including a central cluster rich in T cell receptors (TCRs) and co-stimulatory molecules (cSMAC), a peripheral cluster of adhesion molecules (pSMAC), and a distal region containing molecules such as CD45 (dSMAC)[1][2][3][5]. The **antigen presentation machinery** encompasses the cellular components responsible for processing and presenting antigenic peptides via MHC molecules to T cells, which includes proteases, chaperones, transporter associated with antigen processing (TAP), and MHC class I and II proteins[4]. **Immunological synapse and antigen presentation machinery** are not specific single molecules, receptors, or druggable targets, but rather describe multi-protein complexes and functional cellular platforms essential for orchestrating adaptive immune responses[1][3][4][5]. Accordingly, they are not considered typical therapeutic targets akin to enzymes, receptors, or ion channels, but their components (such as MHC, TCR, CD28, LFA-1, ICAM-1, CD80/86) individually serve as therapeutic or diagnostic targets in immunology, cancer immunotherapy, and autoimmunity[1][3][6]. **Note:** The term provided refers to a process and structural assembly, not a canonical, single molecular target. **Key points:** - The immunological synapse is an interface, not a discrete protein, comprising TCR, MHC, LFA-1, CD28, and other complexes[1][2][3][5]. - Antigen presentation machinery refers to cellular and molecular systems (MHC I/II, processing proteases, etc.) that prepare and display antigenic peptides to the immune system[4]. - Both are fundamental for effective immune surveillance, activation, and effector functions, but their complexity and multi-component nature make them non-traditional or non-druggable targets as a whole[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunological synapse and antigen presentation machinery (IS/APM).